baber/WOPTO huggingface dataset:
Patent CY-1112248-T1 (CY)
Title: Υλικα για οφθαλμικες και ωτορινολαρυγγολογικες συσκευες
Inventor: SCHLUETER DOUGLAS C
IPC: G02B1/04
Filed: 2011-07-13
Abstract: Αποκαλύπτονται μαλακά, υψηλού δείκτη διαθλάσεως, ακρυλικά υλικά για συσκευές. Τα υλικά περιέχουν μακρομερές με υδρόφιλη πλευρική αλυσίδα για την αντοχή στα άστραφτα.
Patent CY-1114186-T1 (CY)
Title: Παραγωγα ιμιδαζολιου ως ανταγωνιστες mglur5
Inventor: JAESCHKE GEORG
IPC: C07D403/04
Filed: 2013-07-22
Abstract: Η παρούσα εφεύρεση σχετίζεται με παράγωγα ιμιδαζολίου του γενικού τύπου I, όπου το R1 σημαίνει αλογόνο, κατώτερο αλκύλιο ή κατώτερο αλκοξύλιο· το R2 σημαίνει κατώτερο αλκύλιο, κατώτερο υδροξυαλκύλιο ή κατώτερο αλκοξυαλκύλιο· το R3 σημαίνει υδρογόνο, κατώτερο αλκύλιο, κατώτερο υδροξυαλκύλιο ή αλκοξυαλκύλιο· το Q σημαίνει είτε -Ν= ή -CH=· το R4 είναι μια ομάδα του τύπου IIα ή IIb(τύπος IIα και ΙΙb) όπου τα Χ, Υ και Ζ είναι ανεξαρτήτως -CH- ή -Ν= και όπου μόνο ένα από τα Χ ή Υ μπορεί να είναι άτομο αζώτου· τα R5 και R6 είναι ανεξαρτήτως υδρογόνο, κατώτερο αλκύλιο, κατώτερο υδροξυαλκύλιο, κατώτερο αλκοξυαλκύλιο, -(CH2)m-(CΟ)O- κατώτερο αλκύλιο, -(CΗ2)m-S(Ο)2-κατώτερο αλκύλιο, -(CΗ2)m-C(Ο)-ΝR’R’’ και όπου το m = 0-3 και τα R’ και R’’ είναι ανεξαρτήτως υδρογόνο ή κατώτερο αλκύλιο· καθώς και με φαρμακευτικώς αποδεκτά άλατα αυτών. Σήμερα εντελώς αναπάντεχα βρέθηκε ότι οι ενώσεις του γενικού τύπου (I) είναι ανταγωνιστές μεταβοτροπικού υποδοχέα γλουταμινικού. Μπορούν να χρησιμοποιηθούν στη θεραπευτική αντιμετώπιση ή την πρόληψη διαταραχών στις οποίες μεσολαβεί υποδοχέας mGluR5.
Patent CY-1115113-T1 (CY)
Title: Παραλλαγμενος συνθετος φαρος στρατιωτικου οχηματος
Inventor: BOLANDER ALBERT J JR
IPC: F21S8/10
Filed: 2014-01-22
Abstract: Μία συγκρότηση σύνθετου φάρου για χρήση σε ένα παραλλαγμένο στρατιωτικό όχημα περιλαμβάνει ένα περίβλημα φάρου χρωματισμένο ώστε να ταιριάζει με το παραλλαγμένο σχήμα του οχήματος. Το περίβλημα του φάρου ορίζει έναν εσωτερικό χώρο, ένα πρώτο άνοιγμα και μία πλειάδα δεύτερων ανοιγμάτων σε επικοινωνία με τον εσωτερικό χώρο. Η συγκρότηση φάρου περιλαμβάνει διαφανείς φακούς προσαρτημένους στο περίβλημα ώστε να καταλαμβάνουν το πρώτο άνοιγμα και μία πλειάδα διάχυτων προσαρτημένων στο περίβλημα ώστε να καταλαμβάνουν την πλειάδα των δεύτερων ανοιγμάτων, με τους διαχύτες έγχρωμους ώστε να ταιριάζουν με το παραλλαγμένο σχήμα του οχήματος. Η συγκρότηση φάρου περιλαμβάνει περαιτέρω μία πλακέτα κυκλώματος διευθετημένη εντός του εσωτερικού χώρου του περιβλήματος φάρου που έχει εγκατεστημένες εκεί πρώτη και δεύτερη πλειάδες διόδων LED. Η πρώτη πλειάδα των διόδων LED είναι σε θέση ώστε να παρέχει φώς διαμέσου των διαυγών φακών και η δεύτερη είναι τοποθετημένη για να προσφέρει φώς διαμέσου των διαχυτών.
Patent CY-1116511-T1 (CY)
Title: Μεθοδος αγωγης του κολπικου ινιδισμου
Inventor: ANTZELEVITCH CHARLES
IPC: A61K31/343
Filed: 2015-07-17
Abstract: Η παρούσα εφεύρεση σχετίζεται με μέθοδο για την αγωγή ή πρόληψη του κολπικού ινιδισμού και/ή του κολπικού πτερυγισμού που περιλαμβάνει την συνχορήγηση μιας συνεργιστικώς θεραπευτικής ποσότητας δρονεδαρόνης ή φαρμακευτικώς αποδεκτού(-ών) άλατος ή αλάτων εξ αυτής και μίας συνεργιστικώς θεραπευτικής ποσότητας ρανολαζίνης ή φαρμακευτικώς αποδεκτού(-ών) άλατος ή αλάτων εξ αυτής. Επίσης παρέχονται και μέθοδοι για την τροποποίηση του κοιλιακού και κολπικού ρυθμού και της συχνότητας. Αυτή η εφεύρεση σχετίζεται επίσης και με φαρμακευτικές φαρμακοτεχνικές μορφές που είναι κατάλληλες για τέτοια συνδυασμένη χορήγηση.
Patent CY-1122604-T1 (CY)
Title: Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης
Inventor: CHAWLA LAKHMIR
IPC: A61K9/00
Filed: 2020-01-13
Abstract: Η παρούσα εφεύρεση σχετίζεται, π.χ., με μία μέθοδο η οποία περιλαμβάνει χορήγηση σε ένα υποκείμενο το οποίο έχει σοκ υψηλής παροχής και το οποίο υποβάλλεται σε αγωγή με μια κατεχολαμίνη σε μια δόση ισοδύναμη με τουλάχιστον περίπου 0,2 mcg/kg/min νορεπινεφρίνης μιας δόσης αγγειοτασίνης II η οποία είναι αποτελεσματική για αύξηση της πίεσης του αίματος του υποκειμένου σε μια μέση αρτηριακή πίεση (MAP) περίπου 65 mm Hg ή μεγαλύτερη, και η οποία είναι αποτελεσματική για μείωση της δόσης της κατεχολαμίνης η οποία απαιτείται για διατήρηση μιας MAP περίπου 65 mm Hg στην ισοδύναμη περίπου 0,05 -2,0 mcg/kg/min νορεπινεφρίνης ή μικρότερη, ή στην ισοδύναμη περίπου 0,05 mcg/kg/min νορεπινεφρίνης ή μικρότερη.
Patent CY-1123298-T1 (CY)
Title: Παραγωγα σουλφαμοϋλπυρρολαμιδιου και η χρηση αυτων ως φαρμακων για τη θεραπευτικη αντιμετωπιση της ηπατιτιδας β
Inventor: VANDYCK KOEN
IPC: C07D207/36
Filed: 2020-05-04
Abstract: Αναστολείς της αντιγραφής του ΗΒV του Τύπου (ΙD) που συμπεριλαμβάνουν στερεοχημικώς ισομερείς μορφές και άλατα, ένυδρα άλατα, επιδιαλυτωμένα σύμπλοκα αυτών, όπου τα Χ, Ra έως Rd και R4 έως R6 έχουν την έννοια όπως ορίζεται στο παρόν. Η παρούσα εφεύρεση αναφέρεται επίσης σε διεργασίες για την παρασκευή των εν λόγω ενώσεων, φαρμακευτικών συνθέσεων που τις περιέχουν και στη χρήση τους, μόνες ή σε συνδυασμό με άλλους αναστολείς του HBV, στην θεραπεία του ΗΒV.
Patent CY-1124817-T1 (CY)
Title: Μεθοδος για την αναλυση γλυκοζαμινογλυκανων, ηπαρινων καi των παραγωγων τους με πυρηνικο μαγνητικο συντονισμο
Inventor: FRANCO GUILLERMO
IPC: G01N33/50
Filed: 2021-10-26
Abstract: Η παρούσα εφεύρεση περιγράφει μία αναλυτική μέθοδο με πυρηνικό μαγνητικό συντονισμό γλυκοζαμινογλυκανών γενικά, και ηπαρινών και ηπαρινών χαμηλού μοριακού βάρους και των παραγώγων τους συγκεκριμένα, η οποία (μέθοδος) επιτρέπει την ταυτοποίηση τους και τη σχετική ποσοτικοποίηση των χαρακτηριστικών σημάτων της με 1H-NMR και 1H-13HSQC.
Patent GR-890300180-T1 (GR)
Title: Solid ester products of sterically hindered polyhydroxymonocarboxylic acids
Inventor: ECKLER PAUL E
IPC: C07C69/675
Filed: 1990-10-31
Abstract: An ester of a sterically hindered polyhydroxymonocarboxylic acid and a polyhydroxy-containing component, which ester is a solid at ambient temperature conditions, comprising the condensation product of said acid selected from the group consisting of dimethylolpropionic acid, trimethylolacetic acid, and mixtures thereof, and said polyhydroxy-containing component selected from the group consisting of pentaerythritol, trimethylolethane, and mixtures thereof, said product having a mol ratio of acid to polyhydroxy-containing component of at least about 1.75, a ring and ball softening point of at least about 50 DEG C, and an acid number of less than about 40. An ester of a sterically hindered polyhydroxymonocarboxylic acid and a polyhydroxy-containing component, which ester is a solid at ambient temperature conditions, comprising the condensation product of said acid selected from the group consisting of dimethylolpropionic acid, trimethylolacetic acid, and mixtures thereof, and pentaerythritol, said product having a mol ratio of acid to pentaerythritol of at least about 0.75, a ring and ball softening point of at least about 50 DEG C, and an acid number less than about 40. An ester of trimethylolacetic acid and trimethylolpropane, which ester is a solid at ambient temperature conditions, comprising the condensation product of said acid and said trimethylolpentane, said product having a mol ratio of acid to trimethylolpentane of at least about 1.75, a ring and ball softening point of at least about 50 DEG C, and an acid number of less than about 40.
Patent GR-940300084-T1 (GR)
Title: Corrosion protection of friction linings.
Inventor: ECKERT ARMIN
IPC: C08L61/06
Filed: 1994-12-30
Abstract: To prevent the corrosion of organically bonded friction linings, a corrosion prevention coating is claimed which comprises     from 45 to 75% by weight of phenolic resin,   from 20 to 40% by weight of inorganic zinc compounds,   from 0 to 10% by weight of synthetic silicic acid, and from 5 to 15% by weight of adhesive based on modified phenolic resin.     Following its application to the lining support plate, the coating is dried until tack-free and is cured together with the pressed-on friction material and, if appropriate, a layer of adhesive applied in between.
Patent HR-P20100420-T1 (HR)
Inventor: VOLPICELLI RAFFAELLA
IPC: C07D407/12
Filed: 2010-07-29
Abstract: Postupak za pripremu d-NBV formule naznačen time da obuhvaća: a)	reakciju 2,2-dimetil-1,3-dioksolan-4-karbaldehida formules vinil Grignardovim reagensom, da bi se dobio spoj formule IIa u obliku dijastereoizomerne smjese (S, R+R, R) b)	reakciju gore navedenog spoja formule IIa sa 2-bromo-4-fluorofenolom, da bi se dobio spoj formule IIIa u obliku dijastereoizomerne smjese (S, R+R, R) c)	reakciju spoja gore navedene formule IIIa s organoboranskim-spojem formule, u kojem je svaki Y siamil grupa, izopropil-prenil grupa, cikloheksil grupa, izopinokamfil grupa i teksil grupa; ili se uzimaju oba Y zajedno s atomom bora, na koji su povezani u obliku borbiciklo[3.3.1]non-9-il grupe ili ostatkom formule: za dobivanje spoja formule IVa u obliku dijastereoizomerne smjese (S, R+R, R), ukojoj je Y gore definiran; d)	cikliziranje gore navedenog spoja formule IVa, da bi se dobio spoj formule Va u obliku dijastereoizomerne smjese (S, R+R, R) i, po želji, razdvajanje složene formule Va (S, R+R, R ) na zaseban dijastereomer Va (S, R) i zaseban dijastereomer Va (R, R); e)	hidroliziranje dijastereoizomerne mješavine iz formule Va (S, R+R, R) ili, alternativno, hidroliziranje odvojenog dijasteromera Va (S, R) i dijasteromera Va (RR), da bi se dobila odgovarajuća dijasteroizomerna mješavina formule VIa (S, R+R, R) ili neovisno, dijasteromer VIa (S, R) i dijasteromer VIa (RR) f)	reakciju dijasteroizomere mješavine formule VIa (S, R+R, R), ili alternativno reakciju odvojenog dijasteromera VIa (S, R) i dijasteromera VIa (R, R) s reaktantom koji može omogućiti uvođenje tosila ili mesila, kao odlazne skupine za dobivanje odgovarajuće dijasteroizomerne mješavine formule VIIa (S, R+R, R) ili neovisno, dijasteromera VIIa (S, R) i dijasteromera VIIa (R, R), pri čemu je L tosil ili mesil; g)	reakciju dijasteroizomerne mješavine formule VIIa (S, R+R, R), ili alternativno reakciju odvojenog dijasteromera VIIa (S, R) i dijasteromera VIIa (R, R) s bazom, za dobivanje odgovarajuće dijasteroizomerne mješavine formule VIIIa (S, R+R, R) ili neovisno, dijasteromera VIIa (S, R) i dijasteromera VIIIa (R, R) i razdvajajući, ako je to slučaj, dijasteroiomernu mješavinu formule VIIIa (S, R+R, R) na zaseban dijasteromer VIIIa (S, R) i zaseban dijasteromer VIIIa (R, R); h)	reakciju odvojeno spoja formule VIIIa (S, R) ili spoja formule VIIIa (R, R) sa zaštićenim H2N-P-aminom, u kojoj je P zaštitna dušikova grupa, da bi se dobio spoj formule IXa (S, R) ili formule IXa (R, R) i)	reakciju spoja formule IXa (S, R) ili spoja formule IXa (R, R) sa spojem formule VIIIa (R, R) ili spojem VIIIa (S, R) odnosno, za dobivanje spojeva formule Xa (S, R, R, R) ili spojeva Xa (R, R, R, S), gdje je spoj formule Xa (S, R, R, R) isti stereoizomera spoja Xa (R, R, R, S), zbog prisutnosti osi simetrije koja sadrži atom dušika u strukturi spoja Xa. j)	skidanje zaštite sa spoja formule Xa kako bi se dobio d-NBV iz gore navedene formule Ia; k)	i, po želji, salifikaciju spoja formule Ia. Patent sadrži još 18 patentnih z
Patent HR-P20100629-T1 (HR)
Inventor: FATHEREE PAUL R
IPC: A61P1/00
Filed: 2010-11-19
Abstract: Spoj u obliku kristalne soli, naznačen time, da je to klorovodična sol spoja 1-izopropil-2-okso-1,2-dihidrokinolion-3-karboksilna kiselina {(1S,3R,5R)-8-[(R)-2-hidroksi-3-(metansulfonil-metil-amino)propil]-8-azabiciklo[3.2.1]okt-3-il}amid ili njegov solvat. Patent sadrži još 19 patentnih zahtjeva.
Patent HR-P20110825-T1 (HR)
Inventor: BUR DANIEL
IPC: C07D249/04
Filed: 2011-11-10
Abstract: Spoj formule (I), naznačen time, da A predstavlja fenil- ili heterociklil-skupinu, gdje su dva supstituenta u 1, 3-rasporedu; ili A predstavlja propan-1,3-diil; E predstavlja *-(C1-C4)alkil-O-, -CH=CH- iligdje zvjezdica označava vezu koja je spojena na R1; Q predstavlja O ili S; R3 predstavlja vodik, (C1-C4)alkil, ciklopropil, (C1-C4)alkoksi-(C1-C2)alkil, benzil ili -CH2CH2C(O)OtBu; R1 predstavlja piridil- ili aril-skupinu, gdje je ta skupina nesupstituirana, mono-, di- ili tri-supstituirana, pri čemu su supstituenti neovisno odabrani iz skupine koju čine halogen, (C1-C4)alkil, (C1-C4)alkoksi, (C1-C4)fluoroalkil, (C1-C4)fluoroalkoksi, di-[(C1-C3)alkil]-amino i (C1-C4)alkoksi-(C1-C2)alkil; iR2 predstavlja -CO-(C1-C3)alkil, -CF2-(C1-C3)alkil, ili -SO2-(C1-C3)alkil; ili sol takvoga spoja. Patent sadrži još 16 patentnih zahtjeva.
Patent SI-1461359-T1 (SI)
Title: Novel anti-igf-ir antibodies and uses thereof
Inventor: GOETSCH LILIANE
IPC: C12N9/99
Filed: 2003-01-20
Abstract: An isolated antibody (Ab), and its functional fragments, that bind to human insulin-like growth factor-1 receptor (IGF-1R) and optionally: (i) inhibit natural binding of insulin-like growth factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine kinase activity of IGF-1R. An isolated antibody (Ab), and its functional fragments, that bind to human insulin-like growth factor-1 receptor (IGF-1R) and optionally inhibit natural binding of insulin-like growth factors (IGF)-1 and/or -2 and/or inhibit specifically tyrosine kinase activity of IGF-1R, is new. Ab comprises: (a) a light chain containing at least one complementarity-determining region (CDR) of one of 3 fully defined sequences comprising 16, 7 or 9 amino acids as given in the specification; or (b) a heavy chain containing at least one of the CDRs of one of 3 fully defined sequences comprising 6, 16 or 8 amino acids as given in the specification or sequences with 80% identity after optimal alignment. Independent claims are also included for the following: (1) murine hybridomas that secrete Ab; (2) an isolated nucleic acid (I) that: (a) is RNA or DNA and encodes Ab or its fragments; (b) is the complement of (a); or (c) has at least 18 nucleotides that can hybridize under stringent conditions with any of six sequences fully defined in the specification that encode the specified CDR, or with sequences having 80% identity after optimal alignment; (3) a vector containing (I); (4) a host cell containing the vector of (3); (5) a non-human transgenic animal containing at least one cell transfected with the vector of (3); (6) producing Ab or its fragments; (7) in vitro diagnosis of diseases induced by over- or under-expression of IGF-1R and or EGFR (epidermal growth factor receptor) by reaction with optionally labeled Ab; and (8) kit for performing method (7). ACTIVITY : Cytostatic; Antipsoriatic. The murine antibody 7C10, specific for IGF-1R, was tested (at 250 Microgram twice a week, intraperitoneally) against MCF-7 breast cancer cells, implanted in nude mice. After 37 days, the mean tumor volume was about 150 mm 3>; compared to about 800 mm 3> for controls and 300 mm 3> for animals treated with 10 Microgram tamoxifen. MECHANISM OF ACTION : Inhibition of signal transduction pathways mediated by IGF-1R, optionally also by epidermal growth factor (EGF) receptor, thus inhibiting growth and/or proliferation of tumor cells, especially where dependent on IGF, EGF, estrogens and/or HER2/neu.
Patent SI-1824504-T1 (SI)
Title: Antitumor combinations containing vegf-trap and 5fu or one of its derivatives
Inventor: VRIGNAUD PATRICIA
IPC: A61K31/00
Filed: 2005-12-02
Abstract: This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.
Patent SI-2513053-T1 (SI)
Title: Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders
Inventor: HOVEYDA HAMID
IPC: C07D413/00
Filed: 2010-12-17
Abstract: The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.
Patent DE-3750569-T2 (DE)
Inventor: HARAGUCHI KEISUKE
IPC: G02B7/10
Filed: 1987-05-12
Granted: 1995-05-04
Abstract: A lens shutter type of camera is provided, having a photographing optical system (1) comprising a zoom lens system (L1, L2), a motor driven cam mechanism (14, 15, 16, 17, 18, 19, 20, 21) for moving the photographing optical system (1, L1, L2) in a zoom range (20d, 21b), thereby varing the focal length of said optical system (1, L1, L2) and for moving said optical system (1, L1, L2) to and from an accommodating position (20a, 20b, 21a) where lenses (L1, L2) of said photographing optical system (1) are in a position behind said zoom range (20e, 21b). In that camera a code plate (90) is provided with an area (Pos2 to PosA) for obtaining focal length information of said optical system (1) and with a detecting area (Pos1) for detecting a transient state (20b) from said zoom range (20d, 21b) to said accommodating position (20a, 21a). The driving of said cam mechanism (14, 15, 16, 17, 18, 19, 20, 21) cannot be stopped when said detecting area (Pos1) signalises a position of the optical system (1, L1, L2) in said transient state (20b, 21a). <IMAGE>
Patent DE-3785273-T2 (DE)
Inventor: GAUGHAN ROGER GRANT
IPC: C08G75/02
Filed: 1987-09-01
Granted: 1993-07-22
Abstract: A process, and product produced therefrom, for preparing a high molecular weight (poly(arylene sulfide ketone) from the reaction product of an alkali metal bisulfide with an alkali metal hydroxide, employing molar excess of alkali metal bisulfide with respect to the alkali metal hydroxide. A process, and product produced therefrom, for preparing a high molecular weight poly(arylene sulfide ketone) employing an alkali metal sulfide and an alkali metal hydrosulfide, wherein the alkali metal sulfide is added in a molar excess with respect to the alkali metal hydrosulfide.
Patent DE-3785690-T2 (DE)
Inventor: MICALE FORTUNATO J
IPC: G02F1/167
Filed: 1987-03-17
Granted: 1993-09-16
Abstract: A process for producing particles for use in electro­phoretic displays, wherein a heavy, solid pigment preferred for its high contrast or refractive index properties is coated with a polymer starting material. The process significantly reduces the specific density of the resultant particle, and creates particles with smooth polymer surfaces that can be chosen for stability in a given electrophoretic carrier fluid, and possess acceptable electrophoretic characteristics.
Patent DE-3855064-T2 (DE)
Inventor: BURG LAWRENCE JAMES
IPC: C12Q1/6893
Filed: 1988-08-01
Granted: 1996-08-29
Abstract: A method is provided for multiplying the number of copies of a target polynucleotide sequence comprising a series of primer hybridization, extending, and denaturing steps to provide an intermediate double-stranded DNA molecule containing a promoter sequence (through the use of a promoter-sequence-containing primer) incorporated upstream from the target sequence. The double-stranded DNA intermediate is then used to grow multiple RNA copies of the target sequence. The resulting RNA copies can be used as target sequences to produce further copies. Multiple cycles of this sort can thereby exponentially increase the number of target sequence copies.
Patent DE-3855941-T2 (DE)
Inventor: ABE NORIYOSHI
IPC: B23K35/02
Filed: 1988-03-23
Granted: 1997-12-04
Abstract: A set of electrodes for a spot welding machine has two electrodes (7 and 9). The first electrode (7) has a distal end slanted at a predetermined angle ( THETA ) to a plane perpendicular to a central axis of the first electrode (7) and is formed with an engaging groove (7c) having a semi-circular cross-section. The other electrode (9) has a distal-end side face (9b) with a curved surface of substantially semi-circular cross-section, whose radius of curvature is smaller than that of the engaging groove (7c) of the first electrode, so that the first distal-end side face can be fitted into the groove. <IMAGE>
Patent DE-3874129-T2 (DE)
Inventor: FOURNIE RENE
IPC: F16L47/16
Filed: 1988-06-02
Granted: 1993-03-04
Abstract: PCT No. PCT/FR88/00275 Sec. 371 Date Apr. 10, 1989 Sec. 102(e) Date Apr. 10, 1989 PCT Filed Jun. 2, 1988 PCT Pub. No. WO88/09898 PCT Pub. Date Dec. 15, 1988.A connection system for pipes made of composite material where each pipe end has an inner sleeve with a radial lip overlapping the pipe end, an outer sleeve attached to each pipe end and a threaded sleeve engaging threads on the outer sleeves to urge the radial lips into engagement.
Patent DE-3881491-T2 (DE)
Inventor: CLERICI MARIO GABRIELE
IPC: C07C231/08
Filed: 1988-12-02
Granted: 1993-10-28
Abstract: N-acyl-anilines are prepared by means of the reaction between a phenol and an amide, by operating at a high temperature, and in the presence of a molecular sieve as the catalyst. In particular, the preparation is disclosed of N-acetyl-para-amino-phenol by means of the reaction of hydroquinone and acetamide.
Patent TR-199901282-T2 (TR)
Inventor: LUBISCH WILFRIED
IPC: A61P43/00
Filed: 1997-11-28
Abstract: Bulus, formül (I)'e ait heterosiklik olarak ikame edilmis benzamitlerle ilgilidir; buradaki R1, R2, R3, R4, R5, X, m ve n; tarifte verilen anlamlara gelecektir. Yeni bilesikler, hastaliklarla savasmak için uygundur.(Formül(I)).
Patent TR-199903054-T2 (TR)
Inventor: KONIG GERD
IPC: C07C229/22
Filed: 1998-06-11
Abstract: Bulus, örnegin XII ve XVI formüllerinin bilesimleri gibi, özellikle kalp ve dolasim sistemi hastaliklarinin tedavisinde eczacilikla ilgili etken maddeler olarak kullanilabilecek, patent istemlerinde tarif edildikleri sekilde pentaeritrit' ten türetilmis yeni bilesimleri tarif etmektedir.        (XII)        (XVI)
Patent DE-60001254-T2 (DE)
Inventor: HILLIGES KLAUS-DIETER
IPC: G06F11/22
Filed: 2000-06-16
Granted: 2003-07-10
Abstract: Disclosed is an automated test equipment - ATE - (200) having a tester-perpin architecture with a plurality of individual decentralized per-pin testing units (700), wherein each per-pin testing unit (700i) being adapted for testing a respective DUT-pin (di) of a device under test - DUT - (600) by emitting stimulus response signals to the respective DUT-pin and/or receiving stimulus response signals from the respective DUT-pin. For testing the DUT, the following steps are executed:   defining - for a testing sequence - the DUT into one or more DUT-cores representing one or more functional units of the DUT and covering one or more DUT-pins of the DUT, and assigning - during the testing sequence - one or more of the per-pin testing units (700i) to one or more ATE-ports (210-240), whereby each ATE-port comprises one or more of the per-pin testing units (700i) and represents an independent functional testing unit for testing one or more of the DUT-cores during the testing sequence.   <IMAGE>
Patent DE-60005341-T2 (DE)
Inventor: SCHIESSER STEFAN
IPC: C08L53/00
Filed: 2000-05-12
Granted: 2004-06-24
Abstract: A profile of a thermoplastic moulding compound for windows and doors is disclosed. The profile is characterised in that the thermoplastic moulding compound comprises a propylene block copolymer with a nucleating agent and a filler, and that the profile (i) has a tensile modulus of at least 2000 MPa, determined according to DIN 53457; (ii) has an impact strength of at least 20 kJ/m<2>, determined according to ISO 179/1eA/23  DEG C; (iii) has a welding factor of at least 0.7, determined according to DIN 53455; and (iv) has a Vicat B softening point of at least 75  DEG C, determined according to ASTM D 1525, condition B. Preferably the polypropylene block copolymer includes two components A and B consisting of A) 80-98 parts by weight of an isotactic polypropylene homopolymer as a coherent matrix component with a decade regularity of > 95 %, and B) 2-20 parts by weight of a copolymer consisting of 50-70 parts by weight of propylene and 30-50 parts by weight of ethylene and/or further C4-C8 alpha-olefins as a dispersed elastomeric component; with a ratio of the intrinsic viscosities of the components B/A of 0.9 to 4.0 and a melt index of the moulding compound of 0.15 to 0.8 g/10 min.